Tag: Psilocybin
-
![Filament Health (FH.NEO) Leading the way in Natural Psychedelics. But Is it a Good Long Term Investment?]()
Filament Health (FH.NEO) Leading the way in Natural Psychedelics. But Is it a Good Long Term Investment?
In this episode, we take a look at a company that’s on a mission to get safe, natural psychedelics into the hands of everyone who needs them, as soon as possible. Filament Health (FH.NEO) is an exclusively natural psychedelic drug development company and received the first-ever psilocybin extraction and standardization patent for a public company…
-
![Filament Health (FH.NE): the natural psychedelic company flying under the radar]()
Filament Health (FH.NE): the natural psychedelic company flying under the radar
For the vast majority of the history of human use of psychedelics, they have been seen as something sacred, a gift from God or mother nature herself. Ayahuasca, which contains DMT, was given out by shamans in the Amazon as a tea. It was a spiritual experience that would purge you of your negative energy…
-
![Pure Extracts Technologies (PULL.C) pushes on and shows no pandemic fatigue]()
Pure Extracts Technologies (PULL.C) pushes on and shows no pandemic fatigue
In the times of yore before COVID-19 sent us scurrying back to our caves for self-reflection and Overlook Hotel style shenanigans, the brass here at Equity Guru sent me on a mission to the snowy wastes of Pemberton, British Columbia. The company I was visiting was Pure Extracts Technologies (PULL.C), a cannabis and hemp biomass…
-
![Cybin (CYBN.NE) gets final approval to list on NYSE American and announces public offering]()
Cybin (CYBN.NE) gets final approval to list on NYSE American and announces public offering
Cybin (CYBN.NE) announced that they have received final approval from the New York Stock Exchange (NYSE) to list its shares on the NYSE American exchange. Beginning next Thursday, on August 5, 2021, Cybin will begin trading on the NYSE American under the ticker “CYBN”. Cybin will continue to trade on the NEO exchange, also under…
-
Cybin (CYBN.NEO): Grown up approach to psychedelics brings half billion valuation… so far
Back in January of this year, we told you about a psychedelics company that was going to come at that sector like many had talked about, but few had achieved. Their angle? Be a biotech company. Don’t dick about with fakey business plans or black velvet paintings of Elvis. No Jamaican B&Bs dressed up as…
-
![Core One Labs (COOL.C) Completes Acquisition of Akome Biotech]()
Core One Labs (COOL.C) Completes Acquisition of Akome Biotech
Core One Labs (COOL.C) has completed the acquisition of Akome Biotech, a psychedelic-based pharmaceuticals company focused on providing effective and safe solutions to patients suffering from stroke and neurological illnesses. “Closing on Akome is an important step for the Company, as we have added an outstanding asset and a strong team. The drug formulations being…
-
![Core One Labs (COOL.C) takes their artificial psilocybin research to UBC]()
Core One Labs (COOL.C) takes their artificial psilocybin research to UBC
Core One Labs (COOL.C) subsidiary, Vocan Biotechnologies, and the University of British Columbia (UBC), came to terms on a collaborative research agreement today, according to a press release. The collaboration gives Vocan access to a well-funded, world-class research facility and team to enhance their position in the nascent psychedelic medicine space, especially given the increasing…
-
![Cybin (CYBN.NE) demonstrates Proof of Concept on CYB003 and CYB004 psychedelic molecules]()
Cybin (CYBN.NE) demonstrates Proof of Concept on CYB003 and CYB004 psychedelic molecules
Cybin (CYBN.NE) announced that they have successfully demonstrated Proof of Concept for their deuterated tryptamine programs, CYB003 and CYB004. The Proof of Concept revolves around the duration of psilocybin. A normal psilocybin experience will last around six hours, and can take up to an hour to begin. However, in their press release, Cybin notes that…
-
![Cybin (CYBN.NE) establishes Clinical Advisory Board as they gear up for trials]()
Cybin (CYBN.NE) establishes Clinical Advisory Board as they gear up for trials
Cybin (CYBN.NE) announced they are forming a Clinical Advisory Board, which will be chaired by Alex Belser, Cybin’s Chief Clinical Officer. The board will consist of Belser (PhD), Maurizio Fava (MD), Lynn Marie Morski (DM) and Anthony Back (MD). All members of the board have professional experience in either medicine or research. Fava, the Psychiatrist-in-Chief…
-
![Delic Holdings (DELC.C) gives Q1, 2021 update on its psychedelic business divisions]()
Delic Holdings (DELC.C) gives Q1, 2021 update on its psychedelic business divisions
On February 5th, 2021 DELIC announced the acquisition of KIC, who over the last 3 years have overseen 4,000 ketamine infusion treatments, while revenues increase to over USD $1.5 million.
